What Acacia Pharma does

Acacia Pharma is a UK-incorporated, US-commercializing hospital pharmaceutical company developing supportive care drugs for patients undergoing surgery, invasive procedures, and chemotherapy. Founded in 2006 and headquartered in Cambridge, UK, with US operations based in Indianapolis, Indiana, Acacia built a focused portfolio of differentiated small-molecule products for the peri-operative and oncology supportive care settings. Its two FDA-approved, commercially marketed products are Barhemsys (amisulpride injection), a selective dopamine D2/D3 receptor antagonist indicated for the treatment and prevention of postoperative nausea and vomiting (PONV) in adults — and notably the first and only antiemetic approved for rescue treatment of PONV despite prophylaxis — and Byfavo (remimazolam for injection), an IV benzodiazepine sedative approved for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less. Byfavo's US rights were in-licensed from Paion UK Limited (assigned by Cosmo Technologies Limited). Both approved products carry patent protection through 2031. A third asset, APD403 (intravenous and oral amisulpride), is a late-stage development candidate for chemotherapy-induced nausea and vomiting (CINV), targeting the oncology customer segment with the same active ingredient as Barhemsys; it had completed proof-of-concept and a Phase 2 dose-ranging study as of the input period.

Acacia commercializes Barhemsys and Byfavo directly in the United States through its own hospital-focused sales organization targeting anesthesia and surgical teams in hospitals and ambulatory surgical centers, with revenue generated from product sales to hospital pharmacies and providers (FY2021 net revenues of US$1.2 million, depressed by COVID-19 hospital access constraints). Pricing is not publicly disclosed. The company historically funded its US commercialization through multiple post-IPO equity placings on Euronext Brussels (notably EUR 27 million in February 2021) and ultimately, after a Board-led strategic alternatives review by Greenhill, agreed to a Court-sanctioned Scheme of Arrangement under which Eagle Pharmaceuticals, Inc. acquired the entire issued share capital for approximately €94.7 million on a fully diluted basis. The Scheme became effective on 9 June 2022; Acacia was re-registered as a private company, delisted from Euronext Brussels, and now operates as a wholly owned subsidiary of Eagle Pharmaceuticals (NASDAQ: EGRX), retaining its UK R&D operations in Cambridge and US headquarters in Indianapolis.

Name

Acacia Pharma

Legal name

Acacia Pharma Group Plc

Website

https://acaciapharma.com

Company type

Private

Founded year

2006

Operating status

Acquired

Headcount range

51–100 employees

Short description

Acacia Pharma is a hospital pharmaceutical company developing and commercializing supportive care drugs — Barhemsys and Byfavo — for patients undergoing surgery and invasive procedures, now operating as a wholly owned subsidiary of Eagle Pharmaceuticals following its June 2022 acquisition.

Ownership category

akta.pro rank

Product category

Hospital Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industry

Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Hospital pharmaceuticals
• Supportive care drugs
• Antiemetic therapy
• Procedural sedation
• Postoperative care

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Technology or R&D, Operations

Revenue model

1. Hospital pharmaceutical product sales: Acacia Pharma generates revenue through direct commercialization of two FDA-approved hospital products (Barhemsys for PONV and Byfavo for procedural sedation) in the US via its own sales organization. Net revenues for FY2021 were US$1.2 million.
2. In-licensed product royalties / commercialization rights: Rights to further develop and commercialize Byfavo are in-licensed from Paion UK Limited pursuant to an assignment from Cosmo Technologies Limited for the US market.

Go-to-market motion1 record

Core offering

Acacia Pharma develops and commercializes differentiated hospital pharmaceutical products for supportive care in patients undergoing surgery, invasive procedures, or chemotherapy. Its marketed portfolio comprises Barhemsys (amisulpride injection) for postoperative nausea and vomiting (PONV) and Byfavo (remimazolam) for procedural sedation, with APD403 in late-stage development for chemotherapy-induced nausea and vomiting (CINV).

Product overview

Acacia Pharma offers a focused portfolio of differentiated hospital pharmaceutical products (not a software platform with modules). The portfolio consists of two FDA-approved, commercially marketed products — Barhemsys® (amisulpride injection) for postoperative nausea & vomiting (PONV) and Byfavo® (remimazolam) for procedural sedation — plus APD403, a late-stage development candidate targeting chemotherapy-induced nausea & vomiting (CINV). The two approved products share the same hospital-channel go-to-market and target anesthesia and surgical teams, while APD403 is intended to extend the franchise to oncologists. All assets are commercial-stage new chemical entities with patent duration through 2031, and Acacia Pharma now operates as a wholly owned subsidiary of Eagle Pharmaceuticals following the June 2022 scheme of arrangement.

Differentiator

Problem solved

Functional benefit

Brands

• Barhemsys®: Amisulpride injection, a selective dopamine (D2 and D3) receptor antagonist approved in the US for the treatment and prevention of postoperative nausea and vomiting (PONV) in adult patients.
• Byfavo®
• APD403

Products and services

• Barhemsys (amisulpride injection)

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• Camurus: Camurus is a European specialty pharma developing and commercializing hospital and opioid-dependence products via its own sales channels, comparable in scale, geography mix, and specialty-hospital GTM approach.
• Paion AG: Paion AG is the originator and licensor of remimazolam (Byfavo) to Acacia for the US market; it is comparable as the developer of one of Acacia's core assets and as a smaller specialty pharma commercializing procedural-sedation agents.

Direct peers

• Cumberland Pharmaceuticals: Cumberland Pharmaceuticals is a US specialty hospital pharma company commercializing a focused portfolio of injectable and hospital-administered products, directly comparable to Acacia's strategy of selling differentiated hospital drugs via a small US salesforce.
• Spectrum Pharmaceuticals: Spectrum Pharmaceuticals is a small US specialty pharma commercializing hospital and oncology supportive-care products, comparable to Acacia in scale, oncology-supportive-care focus, and reliance on a small direct salesforce.
• Heron Therapeutics: Heron Therapeutics is a specialty hospital pharma company focused on supportive care, with approved products spanning postoperative pain and chemotherapy-induced nausea and vomiting (CINV) — directly overlapping Acacia's PONV and CINV franchise and the same hospital prescriber base.
• Helsinn Group: Helsinn is a privately held Swiss specialty pharma company with a portfolio of cancer supportive-care products including Aloxi (palonosetron) for CINV, making it a direct comparator to Barhemsys and APD403 in the same therapeutic category and channel.

Broad incumbents

• Eagle Pharmaceuticals: Eagle Pharmaceuticals is Acacia's parent company and a broader hospital-focused specialty pharma operator with an established US commercial organization; it offers the most direct read on Acacia's commercial potential and integration economics under Eagle's ownership.
• Merck & Co. (Emend / aprepitant franchise): Merck's Emend franchise is a leading CINV antiemetic and defines the standard of care that Acacia's APD403 must displace; it is a comparable incumbent competitor in the same therapeutic setting rather than a business-model peer.
• Pacira BioSciences: Pacira BioSciences is a larger hospital-focused specialty pharma built around non-opioid pain and surgical care products, addressing the same anesthesia and surgical-team call points that Acacia targets with Barhemsys and Byfavo.

Regional players

• Sobi (Swedish Orphan Biovitrum): Sobi is a European-headquartered specialty pharma focused on rare and specialty diseases including hospital products, broadly comparable as a regional specialty pharma with hospital-channel commercialization but operating primarily outside the US market where Acacia is concentrated.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/acaciapharmainc

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acacia Pharma